SEVENFACT
Treatment and control of bleeding episodes in Hemophilia A or B with inhibitors
ApprovedActive
Key Facts
Indication
Treatment and control of bleeding episodes in Hemophilia A or B with inhibitors
Phase
Approved
Status
Active
Company
About Hema Biologics
HEMA Biologics is a private, commercial-stage biotech company founded in 2012 and headquartered in Louisville, Kentucky. Its primary achievement is the FDA approval of SEVENFACT, the first new inhibitor bypassing agent for hemophilia in over two decades, positioning it in the niche but critical hemophilia with inhibitors market. The company operates with a therapeutics business model, generating early revenue from this single commercial product while potentially exploring other rare bleeding disorders. Its strategy includes patient engagement through digital tools like an educational app and support for investigator-initiated research.
View full company profile